OXiGENE In-Licenses Rights to Promising Program for Neuroendocrine Tumors
June 21, 2012 20:50 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., June 21, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced the...
OXiGENE Announces Publication of Key Data Showing Antitumor Activity of ZYBRESTAT(R) Combined With Bevacizumab
June 06, 2012 16:10 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., June 6, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced the...
OXiGENE Reports First Quarter 2012 Financial Results
May 09, 2012 16:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., May 9, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, reported financial...
OXiGENE Announces First Quarter 2012 Earnings Conference Call and Webcast
May 02, 2012 16:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., May 2, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, will report first...
OXiGENE Reports Data Showing Median Survival and One-Year Survival Improvement in Anaplastic Thyroid Cancer Patients Treated With ZYBRESTAT(R) and Chemotherapy
April 30, 2012 12:30 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., April 30, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer, announced today...
OXiGENE Reports Full Year 2011 Financial Results
March 13, 2012 16:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 13, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGND), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye...
OXiGENE Announces Full Year 2011 Earnings Conference Call and Webcast
March 06, 2012 08:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 6, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
OXiGENE to Present at BIO CEO & Investor Conference
February 06, 2012 08:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Feb. 6, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
OXiGENE and Azanta A/S Establish Partnership to Provide ZYBRESTAT(TM) for ATC in Europe on Named Patient, Compassionate Use Basis
December 12, 2011 08:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., and HELLERUP, Denmark, Dec. 12, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat...
OXiGENE Presents Data From FAVOR Study of ZYBRESTAT in PCV
December 07, 2011 08:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Dec. 7, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...